12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Safinamide: Phase III data

Newron said top-line data from the 24-week, double-blind, placebo-controlled, international Phase III SETTLE trial in 549 patients with mid- to late-stage idiopathic PD with motor fluctuations showed that once-daily 50-100 mg safinamide as an add-on to a stable dose of levodopa demonstrated "substantial evidence" of efficacy....

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >